

Republic of Iraq  
Ministry of Higher Education and Scientific Research  
University of Al-Qadisiyah  
College of Veterinary Medicine

## Al-Qadisiyah Journal of Veterinary Medicine Sciences

Editorial Board

# QJVMS



جمهورية العراق  
وزارة التعليم العالي والبحث العلمي  
جامعة القادسية - كلية الطب البيطري

## مجلة القادسية لعلوم الطب البيطري

هيئة التحرير

ISSN(Print): 1818-5746

ISSN(Online): 2313-4429

### قبول نشر

العدد: 1/2 / 16 /

التاريخ: 2017 / 10 / 8



المحترمين

نجلاء عبد الله داوود  
ماجد كاظم الشبلي  
أزهار نوري الموسوي

الى



تحية طيبة.....

يسرنا اعلامكم ان هيئة التحرير في اجتماعها المنعقد قد درست نتائج التقييم العلمي لبحثكم المعنون

(Molecular characterization for Some virulant factors of *Proteus Mirabilis* isolated from patients in Al-Qadisiyah Province).

وفي ضوء ذلك قررت قبول نشره في العدد (2) المجلد (16) من المجلة الذي سيصدر في النصف الثاني للعام 2017

متمنين لكم التوفيق مع فائق الاحترام



أ.د. ضياء حسين جاسم  
رئيس هيئة التحرير  
2017/10/8

Iraq - Diwaniyah - College of Vet. Medicine

جمهورية العراق - الديوانية - كلية الطب البيطري

<http://vmjou.qu.edu.iq>

email: [vmjou@qu.edu.iq](mailto:vmjou@qu.edu.iq)

email: [qjvms@yahoo.com](mailto:qjvms@yahoo.com)

**Antimicrobial Susceptibility and Molecular Characterization For Some  
Virulence Factors of *Proteus Mirabilis* Isolated From Patients In  
AL-Diwaniya Province / Iraq .**

Najlaa Abdallah D. AL-Oqaili , Majed Kadim AL-Shebli , Azhar N.H.Almousawi  
College of Biotechnology      College of Education      College of Pharmacy  
Al-Qadisiya University      Al-Qadisiya University      Al-Qadisiya University  
najlaa67890@gmail.com      Ardkdhm79@gmail.com      az.almousawi@yahoo.com

**Abstract :** Total of 64 Samples clinical isolates were collected from various sources included urine , ear external swab ,wounds swab , burns swab , high cervical and endometrium cervical swab ,which was taken from (in-patients) and (out-patients) in Maternal , and General Teaching Hospital in AL-Diwaniya city during the period from 1/3/2015 till 30/9/2015 . The resistance of bacterial isolates to 12 different antibiotics was tested and isolates showed different resistance to anti- $\beta$ -Lactam including penicillin and Amoxicillin / Clavulanic acid by (100%) , cefotaxime by (86%) , and Cephalexin by (90.62%) , Imipenem by (18.75%) , and Meropenem by (15.62%) . Some of the virulence factors have been studied genetically (20 isolate) ,in terms of the genetic aspect , five genes were obtained for virulence factors and at varying rates , as the urease enzyme *ureC* , fimbriae formation *mrpA* , flagella *flaA* , hemolysin enzyme *hpmA* and biofilm formation *luxS* (60 , 40 ,100 , 45 , 55) % , respectively .

**Keywords:**Antimicrobial susceptibility test , virulence factors genes, PCR, *proteus mirabilis*.

## Introduction

*Proteus mirabilis* is a common causative agent of the severe invasive diseases. This microorganism expresses several virulence factors. *P. mirabilis* can express adhesins, flagella, and toxins. *Proteus* is a gram-negative bacteria associating to the Enterobacteriaceae family. Which is distinct from other species by swarming in the surface of agar (23). *Proteus* is a broad distribution in the environment that puts up a portion of the normal flora in a gastrointestinal tract of the human. It is ranked third in a cause of hospital-acquired infections (42). The opportunistic human pathogens represented by three species: *P. vulgaris*, *P. mirabilis*, and *P. penneri* (21). It is an important source of hospital-acquired infections (17). *P. mirabilis* the main cause of urinary tract infections (31, 33, 37, 12), *P. mirabilis* is a common cause of urinary tract infection, most existing in patients with indwelling catheters and urinary tract structural abnormalities (3), respiratory tract and wounds infections (38), burns and digestive tract infections (44), Ear infection and Otitis media (7). *P. mirabilis* has a wide arrange of cell-associated factors, it can secreted a lot of factors, some of these factors have been closely related with disease producing potential called virulence factors (16, 39), such as swarming, fimbriae, urease, hemolysin, iron acquisition systems (22), protease and Lipopolysaccharides (LPS) (41). This pathogen have developed several pathogenic factors including which listed above which enable them to colonize, survive and grow in the host organism (16, 40).

## **Materials and methods**

### **Specimens' collection**

different Samples such as urine , wound swab , burn swab , high cervical , endometrium cervical and ear external swab, which was taken from (in-patients) and (out-patients) after taken the approval of the patient's in Maternal and General Teaching Hospital in AL- Diwaniya city during the period from 1/3/2015 till 30/9/2015.The collection process has been conducted according to (26).

### **Identification of Bacterial Isolates**

The isolates were identified according to (18) by using traditional microscopic examination (Gram's stain), colony morphological features on MacConkey agar and blood agar, and standard biochemical tests.

### **DNA extraction**

The total genomic DNA of the *P.mirabilis* was isolated using the DNA extraction and purification kit (Geneaid ,USA) according to the manufacturer instructions . DNA preparations were then analyzed by electrophoresis in 1.5% agarose gel .

### **Polymerase chain reaction**

Polymerase chain reaction was used to amplify the entire sequences of the genes studied in this research. The specific primers (Bioneer, Korea) used for the amplification of these genes (45) were shown in (table 1) .

## Agarose gel electrophoresis

The products were separated in 1.5% agarose gel in TBE buffer (pH 8) , stained with ethidium bromide, and photographed in ultraviolet light (14) . The electrophoresis result noticed by using gel documentation system .

### Detection of the virulence factors of *P. mirabilis*

- 1-Hemolysin production
- 2-Urease production
- 3- Biofilm formation
- 4-Detecting flagella
- 5-Detecting fimbriae

Table (1) : The primer of some virulence factors genes in this study

Primer	Sequence	Amplicon
Urease <i>ureC</i>	CAAGCCCAAGAAGGTCTCGT	517bp
	CAAGATGCTCGTCCACGGTA	
Fimbriae <i>mrpA</i>	CGGGTTCTGCTTTAGCTGCA	359bp
	GTTTTGAGCAGCACTTGGGG	
Flagella <i>flaA</i>	ATCAATGCAGCTGCGACACT	445bp
	TGAAGTACCCGCTTGTTGCA	
Hemolysin <i>hpmA</i>	AGGTGCTAAACTGCATGCGA	270bp
	ACAAAAGCACCTTGGTTGCC	
Biofilm formation <i>LuxS</i>	ACGTATGTCTGCACCTGCG	290bp
	CCATAGCTGCCTTCCATGCA	

### **Antimicrobial susceptibility test (AST)**

Determination of antimicrobial agents susceptibility by disk diffusion method (35) ,Which was gotten from BDH London, UK ,which was: penicillin (P) , augmentin (AUG) , gentamycin (GM) , cefotaxime (CTX) , cephalixin (CL), amikacin (AK), imipenem (IMP), Meropenem (MEM), Tobramycin (TOB), Kanamycin (K), Netilmicin (NET) and Streptomycin (S).

The inoculum were prepared by growing of *Proteus mirabilis* on dispersed agar plates, then the colonies grow in the plate transferred by loop into a test tube filled with 3 ml of normal saline. The suspensions density was adapted to 0.5 McFarland standards. The plate surface of Muller-Hinton agar (Himedia India) was inoculated with bacteria by a sterile swab. The swab was soaked into the suspension and pressed into the side of the test tube to discard exuberance fluid, then inoculate the Muller-Hinton agar by streaking method. Antibiotic discs were applied to the inoculated agar and incubated at 37°C overnight. The diameter of zone of growth - inhibition observed was measured and compared to the chart of National Committee for Clinical Laboratory Standards (NCCLS).

### **Results**

Sixty four isolates were identified as *P.mirabilis* consisted of 32 isolates (12.8%) obtained from urine , 17 isolates (9.18%) obtained from external ear, 3 isolates (7.5%) obtained from wounds , 4 isolates (4.7%) obtained from burns and 8 isolates (8.88%) obtained from high cervical and endometrium cervical (table 2).

**Table (2) : Distribution of *P.mirabilis* among various clinical sources .**

Type of samples	No. of samples (%)
Urine	32 (12.8)
External ear	17 (9.18)
Wounds	3 (7.5)
Burns	4 (4.7)
High cervical and endometrium cervical	8 (8.88)
Total	64 (9.84)

### **Susceptibility of *P.mirabilis* isolates to different antimicrobial agents**

(Table3 ) shows a higher percentage of resistance to both Penicillin and amoxicillin with clavulanic acid ( 100% ) , while, the lowest resistance with impenem and meropenem (18.75 , 15.62) % , respectively .

### **Virulence factors of *P.mirabilis***

The results of the PCR for 20 *P.mirabilis* isolates showed that higher percentage of gene *flaA* (100%) , while , the lowest percentage of gene *mrpA* (40%) (table 4) .

Figure (1,2,3,4,5) shows that PCR amplified production for 20 *p.mirabilis* .


**Table (3) : Percentage (%) of antimicrobial resistance and sensitivity of *P.mirabilis***

Antibiotics	Resistance isolates		Sensitive isolates	
	No.	(%)	No.	(%)
Penicillin	64	100	0	0
Augmentin	64	100	0	0
Cefotaxime	55	86	9	14.06
Cephalexin	58	90.62	6	9.37
Impenem	12	18.75	52	81.25
Meropenem	10	15.62	54	84.37
Gentamycin	35	54.68	29	45.31
Amikacin	20	31.25	44	68.75
Tobramycin	49	76.56	15	23.43
Kanamycin	52	81.25	12	18.75
Streptomycin	55	85.93	9	14.06
Netlimicin	52	81.25	12	18.75


**Table (4) :The numbers and percentages of the genes of Virulence factors for 20 *P.mirabilis* isolates .**

Virulence factors genes	No. <i>P.mirabilis</i> isolates	( % )
<i>ureC</i>	12	60
<i>mrpA</i>	8	40
<i>flaA</i>	20	100
<i>hpmA</i>	9	45
<i>luxS</i>	11	55







**Figure (1):** PCR amplified production of *P. mirabilis* isolates using *ureC* gene primers. M:marker ladder (100-2000 bp). Lanes 1-12 the isolates showed positive results with *ureC* gene , (80mA and 100V) for one hour .




**Figure (2):** PCR amplified production of *P. mirabilis* isolates using *mrpA* gene primers. M:marker ladder (100-2000 bp). Lanes 1-8 the isolates showed positive results with *mrpA* gene , (80mA and 100V) for one hour .



**Figure (3):** PCR amplified production of *P. mirabilis* isolates using *flaA* gene primers. M:marker ladder (100-2000 bp). Lanes 1-20 the isolates showed positive results with *flaA* gene , (80mA and 100V) for one hour .



**Figure (4):** PCR amplified production of *P.mirabilis* isolates using *hpmA* gene primers. M:marker ladder (100-2000 bp). Lanes 1-9 the isolates showed positive results with *hpmA* gene,(80mA and 100V) for one hour .



**Figure (5):** PCR amplified production from extracted DNA of *P.mirabilis* isolates using *luxS* gene primers. M: marker ladder (100-2000 bp). Lanes 1-11 the isolates showed positive results with *luxS* gene ,(80mA and 100V) for one hour.

## Discussion

### Isolation and identification

Sixty four isolates were identified as *P.mirabilis* consisted of 32 isolates (12.8%) obtained from urine , 17 isolates (9.18%) obtained from external ear, 3 isolates (7.5%) obtained from wounds , 4 isolates (4.7%) obtained from burns and 8 isolates (8.88%) obtained from high cervical and endometrium cervical .

We analyzed resistance to 12 antibiotics belonging to two groups: beta-lactams and aminoglycosides all isolates showed microbiological resistance Penicillin , amoxicillin with clavulanic acid (100%) , this result agrees with similar studies both of (10,8) , Cefotaxime (86%), this result agrees with (2) about (83%) ,but this current result not agrees with (4) about (100%), also Cephalexin (90.62%) this result agrees with (10) about (80%), but this current result agrees with (8) about (42.85%). As for antibiotic aminoglycosides Gentmycin about (54.68%) this result agrees with (6) about (50%) but not agrees with (20) about (33%), also Amikacin (31.25%) this

result agrees with (11) about (38.4%) but this current result not agrees with (25,6) about (1.6,5)% , respectively. Tobramycin (76.56% )this result agrees with (5) about (81%) but this current result not agrees with (47) about (33.3%) . also antibiotics Kanamycin , Streptomycin and Netl- imicin about (81.25 , 85.93 , 81.25)% , respectively .

### **Virulence factors of *P.mirabilis***

The genotypic characters were tested for 20 *P. mirabilis* isolates in this study in order for detection of the virulence factors. The results of the PCR for the isolates of *P. mirabilis* showed that (60%) isolates were positive for the presence of *ureC* gene, this result not agrees with (43) value *ureC* gene about (100%). Urease is one of the most important factors in *P.mirabilis pathogenesis*. In vitro (on basic urea agar), urease hydrolyzing urea to alkaline ammonia and carbon dioxide, there by increasing the pH and will be changing the color of phenol red indicator to pink (19). But *In vivo* (human body) this enzyme catalyzes the formation of kidney and bladder stones or to encrust or obstruct indwelling urinary (16).

In the current study found *mrpA* gene about (40%) , this result agrees with (1) were value *mrpA* gene (35%), but current study not agrees with (28) were vaule gene (8%) . Basic studies showed that serum from mice infected was reacted firmly to MR/P fimbrial preparations, which revealed that these fimbriae are expressed in vivo (32). MR/P fimbriae expression shown to be extremely induced through infection (24).

The results of this study revealed that all *P.mirabilis* isolates (100%) possessed *flaA* gene, this finding is in agreement with other researches (29) and (9) that conducted in Iraq. They reported the presence of *flaA* gene in

*Proteus* isolates (100%, 86.66%) respectively. While (13) found that (100%) of *P.mirabilis* isolates were carrying *FliL* gene which encodes for the flagellar basal body protein.

In this study the presence of the *hpmA* gene was responsible for hemolysin about (45%), this result agrees with (46) about (46.7%) , while not agrees with (8) about (100%) .

Finally in current study the presence of the *luxS* gene was responsible for biofilm formation about (55%) , this result agrees with (1) who found value *luxS* gene about (47%) .

## التوصيف الجزيئي لبعض عوامل ضراوة *Proteus mirabilis* المعزولة من المرضى في محافظة القادسية

أزهار نوري الموسوي  
كلية الصيدلة  
جامعة القادسية

ماجد كاظم الشبلي  
كلية التربية – علوم الحياة  
جامعة القادسية

نجلاء عبد الله العكيلي  
كلية التقانات الأحيائية  
جامعة القادسية

### الخلاصة

تعد بكتريا *Proteus mirabilis* أحد الأسباب الشائعة لعدد من الأمراض ، تستطيع هذه البكتريا ان تعبر عن عوامل الضراوة منها القابلية على الالتصاق والأسواط والسموم . جمعت ٦٤ عزلة من مصادر سريرية متعددة تضمنت الإدرار والأذن الخارجية والحروق والجروح وأعلى عنق الرحم وبطانة الرحم من المرضى الراقدين والمراجعين لمستشفى الولادة والأطفال التعليمي ومستشفى الديوانية التعليمي للفترة من ٢٠١٥/٣/١ إلى ٢٠١٥/٩/٣٠ . أظهرت هذه البكتريا مقاومة متعددة اتجاه ١٢ نوع من المضادات الحيوية ، إذ أظهرت مقاومة لمضادات البيبتالاکتام المتمثلة Penicillin و Amoxicillin / Clavulanic acid بنسبة (100%) و Cefotaxime بنسبة (86%) و Cephalexin بنسبة (90.62%) و Imipenem بنسبة (18.75) و Meropenem بنسبة (15.62%). كذلك قاومت البكتريا المعزولة مضادات مجموعة الامينوكلايكوسيدات وبنسب مختلفة وهي : Gentamycin و Amikacin و Tobramycin و Kanamycin و Streptomycin و Netlimicin ( 54.68 و 31.25 و 76.56 و 81.25 و 85.93 و 81.25 ) % وعلى التوالي . درست بعض عوامل الضراوة وراثياً لـ 20 عزلة بكتيرية والمتمثلة بجين انزيم اليوريز *ureC* وجين لتكوين الأهداب *mrpA* وجين لتكوين الأسواط *flaA* وجين انزيم الهيمولايسين *hpmA* وجين لتكوين الغشاء الحيوي *luxS* وأظهرت النتائج امتلاك هذه البكتريا لعوامل الضراوة بنسب ( 60 و 40 و 100 و 45 و 55 ) % على التوالي .

## References

1. **Abbas , K. F. ; Al-Khafaji , J.K. and Al-Shukri , M.S. ( 2015 ) .** Molecular Detection of some Virulence Genes in *Proteus mirabilis* Isolation from Hilla province . International J. of research studies in Biosciences ( IJRSB ) , vol.3( 10 ) , pp: 85-89 .
2. **Abdulghani, S. T. (2012) .** The out come of the Misuse of 3rd Generation Cephalosporins In Fallujah City, West of Iraq. Al-Anbar Med. J.,Vol.10(2), pp: 46-50.
3. **Adegbola, R. A.; Old, D. C. and Senior, B. W. (1983).** The adhesins and fimbriae of *Proteus mirabilis* strains associated with high and low affinity for the urinary tract. J. Med. Microbiol. 16:427-431.
4. **AL-Autbi, D. A. K. (2013).** Bacteriological study of some species of Enterobacteriaceae isolated from Hospital birth rooms in Baquba city. Thesis. Diyala University.
5. **Al-Azawy , A.N. ; Al-Taai , H.R.R. and Al-Rajab , I.A.M. (2015) .** Biological study of *Proteus mirabilis* isolated from different clinical sources in AL-Mqdadia city. Diyala J. for pure sci. , Vol.11(2), pp:42-60 .
6. **Al-Bassam , W.W. and Al- Kazaz , A. ( 2013 ) .** The isolation and Characterization of *Proteus mirabilis* from different clinical Samples . J. of Biotechnology Research center ,Vol .7 ( 2 ) .
7. **Al-Bayati, N. S. (2001).** Bacteriological and epidemiological study of chronic superlative otitis media among primary school children in tikrit city. M.Sc. Thesis, College of Medicine, Tikrit University.
8. **Ali , H.H.(2015) .** Molecular study of some virulence factors of *Proteus mirabilis* isolated from urinary tract infection in Al-Qadisiya provence .Thesis, College of Sciences , Al-Qadisiya University .
9. **Ali, H. H. and Yousif, M. G.(2015).** Detection of some virulence factors genes of *Proteus mirabilis* that isolated from urinary tract infection. Research article. Inter. J. of Adv. Res. 3,Issue 1:156-163.
10. **Al-jenahi , M.R.A. (2013) .** Genetic study on isolated *proteus mirabilis* from urinary tract infection in children .Thesis, College of Education , Al-Qadisiya University .
11. **Bahashwan , S.A. And El-Shafey , H.M. ( 2013 ) .** Antimicrobial Resistance Patterns Of *Proteus* Isolates From Clinical Specimens .

European Sci. J.,Vol.9(27) . Taibah University , Al Madinah Al Munawara .

12. **Baldo, C. and Rocha, S. P. D. (2014).** Virulence Factors of Uropathogenic *Proteus Mirabilis* - A Mini Review. Inter. J. of Scient. and Technol. Res. 3: 24-27.
13. **Barbour, E. K.; Hajj, Z. G.; Hamadeh, S.; Shaib, H. A.; Farran, M.T; Araj, G.; Faroon,O.; Barbour, K. E.; Jirjis, F.; Azhar, E.; Kumosani, T. and Harakeh, S.(2012).** Comparison of phenotypic and virulence genes characteristics in human and chicken isolates of *Proteus mirabilis*. Pathogens and Global Health, 106 (6):352-357.
14. **Bartlett, J.M.S. and Stirling, D. (1998).** PCR Protocols: Methods in Molecular Biology.2<sup>nd</sup> . Humana Press Inc. Totowa. NJ.
15. **Coker, C.; Poore, C.A.; Li, X. and Mobley, H.L.T.(2000).** Pathogenesis of *Proteus mirabilis* urinary tract infection. Microbes Infect.2:1497-1505.
16. **Filimon, R. and Iacob, E. (2007).** Incidence of nosocomial infection at the recovery clinic of Iasi hospital in 2004-2005. Rev. Med. Chir. Soc. Med. Iasi. 111(1): 255-257.
17. **Forbes, B.A.; Sahm, D.F. and Weissfeld, A.S. (2007).** Bailey and Scott's Diagnostic Microbiology. 12th ed. Missouri. Mosby Co.:323-333.
18. **Friedrich , A.W.; Koch , R.; Bielaszewska , M.; Zhang , W.; Karch, H. and Mathys,W. (2005) .** Distribution of the Urease gene cluster among urea activity of enterohemorrhagic *Escherichia coli* OH157 isolated from humans. J. of Clin. Micr. 43(2)546-550.
19. **Gangoue-Pieboji , J.; Koulla-Shiro, S.; Ngassam, P. et al. (2006).** Antimicrobial activity against gram negative bacilli from Yaounde Central Hospital, Cameroon. Afr. Health Sci., Vol 6(4), pp: 232-235.
20. **Guentzel M.N. (1996).** *Escherichia, Klebsiella, Enterobacter, Serratia, Citrobacter, and Proteus*. In: *Barron's Medical Microbiology* (Barron 's et al., eds.) (4th ed.). Univ of Texas Medical Branch.
21. **Himpsl, S. D.; Lockett, C. V.; Hebel, J. R.; Johnson, D. E. and Mobley H. L.(2008).** Identification of virulence determinants in uropathogenic *Proteus mirabilis* using signaturetaggedmutagenesis. J. Med. Microbiol. 57:1068-1078.
22. **Jacobsen, S. M., Stickler, D. J. Mobley, H. L. T. and M. E. Shirtliff (2008).** Complicated Catheter-Associated Urinary Tract Infections Due to



*Escherichia coli* and *Proteus mirabilis*. Clinical Microbiology Reviews, 21 (1): 26–59.

23. **Li, X.; Lockett, C. V.; Johnson, D. E. and Mobley, H. L. (2002).** Identification of MrpI as the sole recombinase that regulates the phase variation of MR/P fimbria, a bladder colonization factor of uropathogenic *Proteus mirabilis*. Mol. Microbiol. 45:865-874.
24. **Luzzaro, F., G. Lombardi, M. Perlli, R. Belloni, G. Amicosante, and A. Toniolo. (2001).** Antimicrobial susceptibility testing and ESBL production in clinical isolates of *Proteus mirabilis*: An evaluation with the phoenix™ automated microbiology system. Presented at the 101<sup>st</sup> General Meeting of the Amer. Soc. for Microbiology.
25. **MacFaddin, J.F. (2000).** Biochemical tests for identification of medical bacteria. 3rd ed. Lippincott Williams and Wilkins, USA.
26. **Manos, J. and Belas, R. (2006).** The genera *Proteus*, *Providencia*, and *Morganella*. In The prokaryotes. Vol. 6. 3rd ed. Edited by Dworkin, Springer, New York. pp. 245-269.
27. **Mohammed, G. J. (2014).** Phenotyping and molecular characterization of *proteus vulgaris* isolated from patients with urinary tract infections. Ph. D. Thesis, College of Medicine, Babylon University.
28. **Morgenstein, R. M. (2006).** *Proteus mirabilis* swarming O-antigen, surface sensing, and the Rcs system. Microbiology and Molecular Genetics.
29. **Naber, K.G.; Schito, G.C.; Botto, H.; Palou, J. and Mazzei, T. (2008).** Surveillance study in Europe and Brazil on clinical 1702 aspects and antimicrobial resistance epidemiology in females with cystitis (ARESC): implications for 1703 empiric therapy. Eur. Urol., 54 (12): 1164-1175.
30. **Nielubowicz, G.R. and Mobley, H.L.T. (2010).** Host-pathogen interactions in urinary tract infection. Nat. Rev. Urol. 7(8): 430-441.
31. **O'May, G.A.; Jacobsen, S.M.; Stickler, D.J.; Mobley, H.L.T. and Shirliff, M.E. (2008).** Complicated urinary tract infections due to catheters. The Role of Biofilms in Device-Related Infections. Book. 7142-Chap. 6.
32. **Pearson, M.M.; Sebahia, M.; Churcher, C.; Quail, M.A.; Seshasayee, A.S.; Luscombe, N.M.; Abdallah, Z. et al. (2008).** Complete genome sequence of uropathogenic *Proteus mirabilis*, a master of both adherence and motility. J. Bacteriol. 190(11): 4027- 4037.

33. **Pellegrino, R.; Scavone, P.; Umpiérrez, A.; Maskell, D.J. and Zunino, P. (2013).** "*Proteus mirabilis* uroepithelial cell adhesin (UCA) fimbria plays a role in the colonization of the urinary tract", *Pathogens and Disease*, 67.104-107.
34. **Ranjbar-Omid, M. ; Arzanlou, M.; Amani, M.; Al-Hashem, S.K.S.; Mozafari, N. A. and Doghaheh, H. P. (2015).** Allicin from garlic inhibits the biofilm formation and urease activity of *Proteus mirabilis* *in vitro*. *FEMS. Microbiol. Letters*, 362 Issue 9.
35. **Rozalski, A.; Torzewska, A.; Moryl, M.; Kwil, I.; Maszewska, A.; Ostrowska, K. et al.(2012).** *Proteus* sp.- an opportunistic bacterial pathogen -classification, swarming growth, clinical significance and virulence factors. *Folia Biologica. et. Oecologica*. 8:1-17.
36. **Stamm, W.E. (1999).** Urinary Tract Infections. In *Clinical Infectious Disease: A practical approach*, Root, K. (ed). P: 649-656. Oxford University Press, Inc, New York.
37. **Takeuchi ,H.; Yamamoto,S.; Terai,A.; Kurazono,H.; Takeda,Y.; Okada,Y.and Yoshida,O.(1996).** Detection of *Proteus mirabilis* urease gene in urinary calculi by polymerase. chain reaction *International journal of Urology* , Vol 3(3), pp:202-206 .
38. **Thaler, E. R. and Kennedy, D. W. (2000).** Cited in human, H.D.; Dupont, H.L.; Gradner, .L.B. and Griffin, J.W. *Textbook of internal medicine*.4th ed. Wolters Kluwer Company. USA.
39. **Untergasser , A. ; Nijveen , H. ; Rao, X. ; Bisseling , T. ; Geurts , R. and Leunissen , J. A. (2007).** Primer3Plus, an enhanced web interface to Primer3. *Nucleic Acids Res.* 35(Web Server issue), pp:71-74.
40. **Uphoff , TS. and Welch , RA. (1990) .** Nucleotide sequencing of the *proteus mirabilis* calcium – independent hemolysin genes (hpmA and hpmB) reveals sequence similarity with the *serratia marcescens* hemolysin genes (shlA and shlB) . *J. of bacterial.* , Vol.173(3), pp: 1206-1216 .
41. **Winokur , P. L.; Canton, R.; Casellas, J-M. and Legakis, N. (2001).** Variations in the performance of strains expressing an extended-spectrum  $\beta$ -Lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region. *Clinical Infections Diseases.* , Vol.32( 2), pp: 94-103.